Where does GLUE stock trade?

Monte Rosa Therapeutics Inc. (GLUE) is listed on NASDAQ.

What sector and industry is GLUE in?

Monte Rosa Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.

When did Monte Rosa Therapeutics Inc. go public?

Monte Rosa Therapeutics Inc. (GLUE) completed its IPO in 2021.

What are analysts saying about GLUE?

Monte Rosa Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight with a $1100.00 price target on 2024-12-19. Recent price targets range from $1100.00 to $2200.00.

What companies are similar to GLUE?

Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare GLUE side-by-side with any of them on Quantisnow.

How can I track GLUE on Quantisnow?

Quantisnow aggregates Monte Rosa Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLUE to receive live email and push alerts on every new disclosure.

GLUE

NASDAQ

Monte Rosa Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2021

$17.57-0.16 (-0.93%)

News25/Ratings11

Price$17.57+0.10 (+0.54%)

01:30 PM07:45 PM

News · 26 weeks590%

2025-12-072026-05-31

Mix3090d

Insider11(37%)
SEC Filings9(30%)
Other8(27%)
Offering2(7%)

Latest news

25 items

1dINSIDER
President & CEO Warmuth Markus sold $106,253 worth of shares (5,466 units at $19.44) as part of a pre-agreed trading plan, decreasing direct ownership by 0.91% to 594,538 units (SEC Form 4)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
1dPR
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 20,050 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $19.67 as reported by Nasdaq on June 1, the effective date of the grant or the "Grant Date", which will ve
2dINSIDER
Chief Scientific Officer Townson Sharon exercised 6,000 shares at a strike of $6.14 and sold $119,220 worth of shares (6,000 units at $19.87) as part of a pre-agreed trading plan (SEC Form 4)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
5dINSIDER
Chief Operating Officer Champoux Jennifer exercised 2,175 shares at a strike of $3.98 and sold $43,500 worth of shares (2,175 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
8dINSIDER
Chief Operating Officer Champoux Jennifer exercised 2,176 shares at a strike of $3.98 and sold $41,344 worth of shares (2,176 units at $19.00) as part of a pre-agreed trading plan (SEC Form 4)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
12dINSIDER
Director Manning Anthony M. exercised 10,000 shares at a strike of $4.16 and sold $180,100 worth of shares (10,000 units at $18.01) (SEC Form 4)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
13dSEC
SEC Form 144 filed by Monte Rosa Therapeutics Inc.
144 - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
14dPR
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Oncology Innovation Summit (virtual) – fireside chat, May 27, 2026, at 12:00 p.m. ETJefferies Global Healthcare Conference in New York – fireside chat, June 4, 2026, at 11:40 a.m. ET Webcasts of the fireside chats will be accessible via the "Events & Presentations" section of Monte Rosa's website at ir.monterosatx.com, and archived versions will be made available for 30 days following the present
18dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
19dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
SCHEDULE 13G/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
27dSEC
SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.
10-Q - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
27dSEC
Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
27dPR
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with elevated CVD risk anticipated in H2 2026 Company expects to initiate multiple MRT-8102 Phase 2 studies, including in patients with elevated atherosclerotic risk in H2 2026, in patients with gout flares in Q4 2026/Q1 2027, and in patients with moderate to severe hidradenitis suppurativa in H1 2027 Presented positive interim Phase 1/2 clinical data of GSPT1-directed MGD MRT-2359 in combination with an AR inhibitor in mCRPC patients with AR mutations; initiation of Phase 2 study evaluating MRT-2359
29dINSIDER
President & CEO Warmuth Markus sold $103,447 worth of shares (5,467 units at $18.92) as part of a pre-agreed trading plan, decreasing direct ownership by 0.90% to 600,004 units (SEC Form 4)
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
29dPR
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to four newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 38,925 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $18.80 as reported by Nasdaq on May 1, 2026, the effective date of the grant or the "Grant Date", which wil
35dSEC
SEC Form DEFA14A filed by Monte Rosa Therapeutics Inc.
DEFA14A - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
35dSEC
SEC Form DEF 14A filed by Monte Rosa Therapeutics Inc.
DEF 14A - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)
44dPR
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectivity and reduced off-target activity compared to CDK2 inhibitors Oral presentation on April 21, 2026, at 2:30 p.m. PT BOSTON, April 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1 (CCNE1)-directed MGD, MRT-55811, to treat CCNE1-amp
48dSEC
SEC Form 144 filed by Monte Rosa Therapeutics Inc.
144 - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
49dINSIDER
SEC Form 4 filed by Warmuth Markus
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
54dINSIDER
SEC Form 4 filed by Nickson Philip
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
57dINSIDER
SEC Form 4 filed by Bowen Matthew
4 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
57dINSIDER
SEC Form 3 filed by new insider Bowen Matthew
3 - Monte Rosa Therapeutics, Inc. (0001826457) (Issuer)
76dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Monte Rosa Therapeutics Inc.
SCHEDULE 13D/A - Monte Rosa Therapeutics, Inc. (0001826457) (Subject)
77dSEC
SEC Form S-8 filed by Monte Rosa Therapeutics Inc.
S-8 - Monte Rosa Therapeutics, Inc. (0001826457) (Filer)

Analyst ratings

Last 11

Dec 19Wells Fargo•Update
Equal Weight$11.00$14.00▼ 37.4%
Feb 15Wedbush•Update
Outperform$11.00▼ 37.4%
Jan 3Wells Fargo•Update
Overweight$18.00▲ 2.5%
Oct 13UBS•Update
Buy$22.00▲ 25.2%
Aug 15Jefferies•Update
Buy$20.00▲ 13.9%
Apr 28Credit Suisse•Update
Neutral$19.00▲ 8.2%
Feb 10Wells Fargo•Update
Equal-Weight$19.00▲ 8.2%
Oct 14SVB Leerink•Update
Mkt Perform$20.00▲ 13.9%
Jul 19Guggenheim•Update
Buy$30.00▲ 70.8%
Jul 19Piper Sandler•Update
Overweight$40.00▲ 128%
Jul 19JP Morgan•Update
Overweight$38.00▲ 116%

Short volume

27d, FINRA Reg SHO

73.9%Jun 2

27d avg 70.5%+3.4pp

Apr 24Short / total volumeJun 2

Short236.9KTotal320.7K

Options

5 expirations

Jun 18, 202614d

IV 88.5%5 exp · 100

Callsstrike · last · iv · Δ

12.50---
15.00-95%0.82
17.502.28--
20.001.0099%0.30

Putsstrike · last · iv · Δ

12.50---
15.000.45--
17.500.32--
20.00-71%-0.79

Peers

Quick links

GLUE FAQ

6 questions

Where does GLUE stock trade?
Monte Rosa Therapeutics Inc. (GLUE) is listed on NASDAQ.
What sector and industry is GLUE in?
Monte Rosa Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
When did Monte Rosa Therapeutics Inc. go public?
Monte Rosa Therapeutics Inc. (GLUE) completed its IPO in 2021.
What are analysts saying about GLUE?
Monte Rosa Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight with a $1100.00 price target on 2024-12-19. Recent price targets range from $1100.00 to $2200.00.
What companies are similar to GLUE?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare GLUE side-by-side with any of them on Quantisnow.
How can I track GLUE on Quantisnow?
Quantisnow aggregates Monte Rosa Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GLUE to receive live email and push alerts on every new disclosure.